Press Detail





Biotest AG: Nabi shareholders approve sale of Biologics Business Unit to Biotest

Biotest AG / Acquisition

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------

Nabi shareholders approve sale of Biologics Business Unit to Biotest

· Transfer of almost 500 employees planned for December
· New syndicated loan agreement signed

Boca Raton / Dreieich, 9 November 2007. At the Annual Shareholders’ Meeting
held yesterday in Maryland, the shareholders of Nabi Biopharmaceuticals
Corp., Boca Raton (Florida, USA), approved the sale of the Biologics
Business Unit to Biotest AG with an overwhelming majority (98%). The
company’s plasma protein activities are pooled in this business unit.
Biotest expects that the transaction will be completed by the end of this
year as planned.

The acquisition will enhance Biotest’s position, making it a global
provider of plasma proteins. At the same time, the company’s plasmapheresis
pharmaceutical production capacity will be expanded significantly and the
portfolio in clinical development will also be broadened. Professor Gregor
Schulz, Chairman of the Board of Biotest AG, commented, 'The shareholders’
approval means that we have cleared an important hurdle. We will now
rapidly implement the global production, sales and development strategy in
the Pharmaceutical division.'

Immediately after receiving the shareholders’ approval, Biotest announced
that it will shortly offer employment contracts to around 500 employees of
the Biologics Business Unit so that they will join the Biotest team when
the purchase agreement comes into force in December. Approximately 60% of
the new staff members are employed in the nine plasmapheresis centres
located in seven US federal states, with the remaining employees working in
Pharmaceutical Production, Sales, Clinical Development and management in
the Boca Raton headquarters.

The financing of the transaction has been secured by a new syndicated loan
agreement worth € 175 million, which was signed yesterday. Commerzbank is
the lead manager of the banking consortium, which also includes
HypoVereinsBank, Deutsche Bank and WestLB. The new agreement comprises the
refunding in full of the existing Biotest financing.

Disclaimer

This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and asset
situation of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.

About Biotest

Biotest AG, Dreieich, Germany, is a company that researches and
manufactures pharmaceutical, biotherapeutic and diagnostic products and has
specialised in immunology and haematology. In its Pharmaceutical segment,
Biotest develops immunoglobulins, clotting factors and albumins based on
human blood plasma. These are used for diseases of the immune system or
haematopoietic system. In the Biotherapeutic segment, Biotest researches
into the clinical development of monoclonal antibodies, including in the
indications of rheumatoid arthritis and blood cancer. The Diagnostic
segment spans reagents and serology and microbiology systems which are
used, for example, in blood transfusions. Biotest has around 1,200
employees worldwide and its shares are listed in the Frankfurt Stock
Exchange's Prime Standard.

Biotest AG: 
Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
Dr. Marion Wendorff, Tel: +49 (0) 6103 801-520, e-mail:
marion_wendorff@biotest.de
Fax: +49 (0) 6103 801-347

WKN, ISIN ordinary share: 522720, DE0005227201
WKN, ISIN preference share: 522723, DE0005227235
Listed: Prime Standard/official trading
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart 
09.11.2007  Financial News transmitted by DGAP
----------------------------------------------------------------------
 
Language:     English
Issuer:       Biotest AG
              Landsteinerstr. 5
              63303 Dreieich
              Deutschland
Phone:        +49 - 6103 / 801 - 0
Fax:          +49 - 6103 / 801 - 150
E-mail:       mail@biotest.de
Internet:     www.biotest.de
ISIN:         DE0005227201, DE0005227235
WKN:          522720, 522723
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, Hamburg, Stuttgart
 
End of News                                     DGAP News-Service
 
---------------------------------------------------------------------------